Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Australian Clinical Labs Ltd ( (AU:ACL) ) is now available.
Australian Clinical Labs Ltd has announced an update on its ongoing on-market buy-back program, with a total of 101,866 ordinary fully paid securities bought back on the previous day, bringing the total to 2,059,874 securities. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is known for its diagnostic testing services and plays a significant role in the medical testing market in Australia.
Average Trading Volume: 793,367
Technical Sentiment Signal: Buy
Current Market Cap: A$548.7M
See more insights into ACL stock on TipRanks’ Stock Analysis page.